Epigral

Ahmedabad, India Founded: 1995 • Age: 31 yrs
Essential derivatives and specialty chemicals are manufactured for various industries.
Annual revenue $294.2M Latest available
Total funding $11.5M 1 rounds
Employees 1950 Tracked headcount
Investors 1 Known backers
Products 5 Services tracked
Competitors - Brand Intelligence

About Epigral

Epigral is a company based in Ahmedabad (India) founded in 1995 by Anand Patel, Jayanti Patel, Ramesh Patel, Natwarlal Patel, and Ashish Soparkar. Epigral has raised $11.5 million across 1 funding round from investors including International Finance Corporation. The company has 1,950 employees as of March 31, 2024. Epigral offers products and services including Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes.

  • Headquarter Ahmedabad, India
  • Employees 1950 as on 31 Mar, 2024
  • Founders Anand Patel, Jayanti Patel, Ramesh Patel, Natwarlal Patel, Ashish Soparkar
  • Stage Public
  • Sectors
    Chemicals & Materials
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Epigral Ltd
Operational Areas
Chemicals & Materials → Specialty & Industrial Chemicals Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $294.16 M (USD)
    32.72
    as on Mar 31, 2024
  • Net Profit
    $41.82 M (USD)
    82.62
    as on Mar 31, 2024
  • EBITDA
    $80.26 M (USD)
    50.42
    as on Mar 31, 2024
  • Total Equity Funding
    $11.5 M (USD)

    in 1 rounds

  • Latest Funding Round
    $11.5 M (USD), Series B

    Jun 01, 2008

  • Investors
  • Employee Count
    1950

    as on Mar 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Epigral

Epigral is a publicly listed company on the NSE with ticker symbol EPIGRAL in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NSE · Ticker: EPIGRAL · Sector: Process industries · India

Products & Services of Epigral

Epigral offers a comprehensive portfolio of products and services, including Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes.

Product name locked
Category locked
Primary

Produces caustic soda and chlorine for various industrial uses.

Product name locked
Category locked
Locked

Used in paper, textiles, and chemicals as an eco-friendly agent.

Product name locked
Category locked
Locked

Key component for epoxy resins and pharmaceuticals from renewable sources.

Product name locked
Category locked
Locked

Provides resin and compounds for pipe manufacturing in construction.

Product name locked
Category locked
Locked

Includes compounds for pharmaceuticals and refrigerant production.

People of Epigral

Headcount 500-1000
Employee Profiles 28
Employee Profiles
People
Nakkina Veerabhadra Swamy
Deputy Manager
People
Milind Kotecha
Investor Relations, Corporate Communication And Strategy
People
Ankur Singhal
Zonal Sales Head
People
Sanjay Jain
Chief Financial Officer

Unlock access to complete

Funding Insights of Epigral

Epigral has successfully raised a total of $11.5M through 1 strategic funding round. The most recent funding activity was a Series B round of $11.5 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Epigral

Epigral has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include International Finance Corporation.

All
Venture Fund
Investor Description Founded Year Domain Location
IFC is focused on private sector development in emerging markets.
Locked Locked Locked
Premium access

Investor details for Epigral

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Epigral

Investments
Premium access

Investment portfolio details for Epigral

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Epigral

Premium access

Detailed financials for Epigral

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Epigral Comparisons

Epigral Primary company
Description
Essential derivatives and specialty chemicals are manufactur...
Location
Ahmedabad, India
Founded Year
1995
Annual Revenue
$294.16 M (USD)
Net Profit
$41.82 M (USD)
EBITDA
$80.26 M (USD)
Employees
1,950
As of 2024
Premium access

Peer comparison for Epigral

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Epigral

Premium access

Detailed competitors of Epigral

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Epigral

Premium access

Complete news archive for Epigral

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Epigral

Epigral was founded in 1995 and raised its 1st funding round 13 years after it was founded.

Epigral is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Epigral is a funded company, having raised a total of $11.5M across 1 funding round to date.

As of Mar 31, 2024, the latest employee count at Epigral is 1,950.

Annual revenue of Epigral is $294.16M as on Mar 31, 2024.

Epigral Limited was founded in 1995 and is headquartered in Ahmedabad, India. Operations are focused on the production of chemicals utilized across multiple sectors within the Indian market, where a notable presence has been established. Emphasis is placed on safety protocols and quality standards through ongoing employee training and adherence to secure work practices. Various essential and specialty chemicals are supplied to support industrial applications.

Epigral offers Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes.

Yes, Epigral is publicly traded on NSE under the ticker symbol EPIGRAL.

Epigral has 1 investor. Key investors include International Finance Corporation.

The ticker symbol of Epigral is EPIGRAL on NSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available